UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 11, 2023
STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)
Delaware
| 000-51481
| 13-3986004
|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania | | 19044
|
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant's telephone number, including area code: 215-619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.001 par value per share
| SSKN
| The NASDAQ Stock Market LLC
|
| Item 7.01. | Regulation FD Disclosure. |
On July 11, 2023, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing that the Journal of Clinical and Aesthetic Dermatology (JCAD) published a review and an expert perspectives article in the June 2023 Supplemental edition titled, “Photopneumatic Technology for the Treatment of Mild-to-Moderate Acne Vulgaris.”. In the review, Gilly Munavalli, MD, highlighted the TheraClear®X system, which included its mechanism of action, key features of the device, and the clinical outcomes experienced. Dr. Munavalli also recounted anecdotal results of using the device in the treatment of acne. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. | Financial Statements and Exhibits. |
The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be “filed”:
| Exhibit No. | Exhibit Description |
| | |
| Press release dated July 11, 2023, issued by Strata Skin Sciences, Inc. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | STRATA SKIN SCIENCES, INC. | |
| | | | |
| Date: July 11, 2023 | By: | /s/ Christopher Lesovitz | |
| | | Christopher Lesovitz | |
| | | Chief Financial Officer | |
